Vigil Neuroscience News

Express News | JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target

Moomoo 24/7Apr 18 13:39 ET

Vigil Neuroscience Inc: A Strong Buy on Promising ALSP Drug Trial Outcomes and Biomarker Breakthroughs

TipRanksApr 18 00:25 ET

Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts

TipRanksMar 29 04:27 ET

Vigil Neuroscience Is Maintained at Buy by HC Wainwright & Co.

Vigil Neuroscience Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 27 09:36 ET

Express News | HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Maintains $24 Price Target

Moomoo 24/7Mar 27 09:32 ET

Vigil Neuroscience Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 724.54% HC Wainwright & Co. $24 → $24 Maintains Buy 12/19/2023 37.42% Morgan Stanley $13 → $4 D

BenzingaMar 27 09:22 ET

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)

TipRanksMar 27 07:30 ET

Vigil Neuroscience's Funding Peril: Navigating Market Turbulence in Equity Capital Raises

TipRanksMar 27 02:02 ET

Vigil Neuroscience GAAP EPS of -$0.57 In-line

Seeking AlphaMar 26 15:36 ET

Buy Rating Affirmed: Vigil Neuroscience's Advancing TREM2 Programs and Strong Financial Position

TipRanksMar 26 13:05 ET

Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating

Vigil Neuroscience (VIGL) has an average rating of outperform and price targets ranging from $4 to $24, according to analysts polled by Capital IQ. Price: 2.89, Change: -0.12, Percent Change: -3.83

MT NewswiresMar 26 11:53 ET

Vigil Neuroscience: Q4 Earnings Insights

Vigil Neuroscience (NASDAQ:VIGL) reported its Q4 earnings results on Tuesday, March 26, 2024 at 07:05 AM.Here's what investors need to know about the announcement.EarningsVigil Neuroscience missed est

BenzingaMar 26 09:20 ET

Express News | Vigil Neuroscience Q4 EPS $(0.57) Misses $(0.53) Estimate, Cash Balance of $117.9M

Moomoo 24/7Mar 26 07:28 ET

Vigil Neuroscience 4Q Loss/Shr 57c >VIGL

Vigil Neuroscience 4Q Loss/Shr 57c >VIGL

Dow JonesMar 26 07:06 ET

Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evalu

Dow JonesMar 26 07:05 ET

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Yahoo FinanceMar 24 09:15 ET

Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer

Vigil Neuroscience (VIGL) said Wednesday that it appointed Petra Kaufmann as chief medical officer, succeeding Christopher Silber. Kaufmann was previously chief medical officer at Affinia Therapeutics

MT NewswiresMar 20 13:37 ET

Press Release: Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology

Dow JonesMar 20 07:05 ET

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative

GlobeNewswireMar 13 07:05 ET

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative

GlobeNewswireMar 12 07:05 ET